CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and Its Anti-tumour Effect in Adult Patients With CD44v6 Expressing Solid Tumours

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06639191
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:31.671592+00:00
Published At: 2026-01-30T00:00:00+00:00
Record Updated At: 2026-01-30
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Thyroid Gland Anaplastic Carcinoma", "Poorly Differentiated Thyroid Carcinoma", "Cancer Head and Neck", "Cervix Carcinoma", "Vulvar Cancer, Stage IV", "Non-small Cell Lung Cancer Stage IV"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-30"
protocolSection.identificationModule.nctId: "NCT06639191"
protocolSection.identificationModule.officialTitle: "A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and Its Anti-tumour Effect in Adult Patients With CD44v6 Expressing Solid Tumours"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["EARLY_PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.